Suppr超能文献

人型支原体和解脲脲原体对两种新型喹诺酮类药物(司帕沙星和WIN 57273)的敏感性

Susceptibilities of Mycoplasma hominis and Ureaplasma urealyticum to two new quinolones, sparfloxacin and WIN 57273.

作者信息

Kenny G E, Cartwright F D

机构信息

Department of Pathobiology, University of Washington School of Public Health and Community Medicine, Seattle 98195.

出版信息

Antimicrob Agents Chemother. 1991 Jul;35(7):1515-6. doi: 10.1128/AAC.35.7.1515.

Abstract

Mycoplasma hominis was highly susceptible to two new quinolones, with MICs for 90% of isolates tested of 0.004 micrograms/ml for WIN 57273 and 0.063 micrograms/ml for sparfloxacin, which were activities much greater than the 1 microgram/ml found for ofloxacin and tetracycline. Although Ureaplasma urealyticum was less susceptible, the MICs for 90% of isolates tested of 0.25 micrograms/ml for WIN 57273 and 0.5 micrograms/ml for sparfloxacin were four- to eightfold greater than those found for ofloxacin (2 micrograms/ml) and tetracycline (2 micrograms/ml). The finding that U. urealyticum and M. hominis are more susceptible to WIN 57273 and sparfloxacin than they are to other quinolones suggests that these quinolones may be therapeutically useful.

摘要

人型支原体对两种新喹诺酮类药物高度敏感,对于所测试的90%的分离株,WIN 57273的最低抑菌浓度(MIC)为0.004微克/毫升,司帕沙星的MIC为0.063微克/毫升,其活性远高于氧氟沙星和四环素的1微克/毫升。虽然解脲脲原体的敏感性较低,但对于所测试的90%的分离株,WIN 57273的MIC为0.25微克/毫升,司帕沙星的MIC为0.5微克/毫升,分别比氧氟沙星(2微克/毫升)和四环素(2微克/毫升)高4至8倍。解脲脲原体和人型支原体对WIN 57273和司帕沙星比对其他喹诺酮类药物更敏感,这一发现表明这些喹诺酮类药物可能具有治疗作用。

相似文献

引用本文的文献

本文引用的文献

5
Fluoroquinolone antimicrobial agents.氟喹诺酮类抗菌剂。
Clin Microbiol Rev. 1989 Oct;2(4):378-424. doi: 10.1128/CMR.2.4.378.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验